QEL-001

DRUG2 trials

Sponsors

Quell Therapeutics Limited

Conditions

Liver DiseasesLiver FailurePrevention of liver transplant rejectionRejection; Transplant, Liver

Phase 1

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

Active, not recruitingNCT05234190

Quell Therapeutics LimitedLiver Diseases, Liver Failure, Rejection; Transplant, Liver

Start: 2022-01-21End: 2040-09-01Target: 33Updated: 2026-07-02

A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg patients that have received an HLA-A2pos liver transplant.

Active, not recruitingCTIS2024-516193-30-01

Quell Therapeutics LimitedPrevention of liver transplant rejection

Start: 2023-10-02Target: 14Updated: 2025-04-15